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Patient- derived cancer organoid culture is an important live material that reflects 
clinical	heterogeneity.	However,	the	limited	amount	of	organoids	available	for	each	
case	as	well	as	the	considerable	amount	of	time	and	cost	to	expand	in	vitro	makes	it	
impractical to perform high- throughput drug screening using organoid cultures from 





resulted in minimal changes of morphological and genomic status, and xenograft 
tumor	 generation	 efficiently	 expanded	 the	 number	 of	 CTOS	 to	 evaluate	 multiple	
drugs.	Our	panel	of	colorectal	cancer	CTOS	lines	exhibited	diverse	sensitivities	to	the	
hit compounds, demonstrating the usefulness of this system for investigating highly 
heterogeneous disease.
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1  | INTRODUC TION
Inter-	patient	variations	in	sensitivity	to	therapeutics	are	a	challeng-
ing	 issue	 in	 clinical	 practice,	 making	 it	 increasingly	 important	 to	
obtain tumor samples from individual cancer patients for both de-
velopment of therapeutics and personalized medicine. To determine 
the portion of the population in which a drug will be effective and to 
identify	biomarkers	to	demarcate	potential	responders,	it	is	essential	
to develop systems in which drugs can be tested on materials retain-
ing the heterogeneous characteristics of the original disease.1-3
To assess the responses of cancer cells to various stimuli, includ-
ing anti- cancer drugs, culture of cancer cells is required. Established 
cancer cell lines have historically been the pillar of such in vitro mod-
els. The simplicity and reproducibility of cancer cell lines enables 
drug testing and screening.4,5	However,	 prolonged	 in	vitro	 culture	
of cancer cells promotes cell conversion, probably by selection or 
accumulation of genetic alterations, which is a caveat for the devel-
opment of personalized therapeutic approaches and of new drugs.5
Over	the	past	decade,	primary	culture	has	been	significantly	im-
proved by overcoming complicated procedures, poor reproducibil-
ity and uncontrolled co- existence of various cell types.1,6,7 Modern 
cultures are expected to retain the characteristics of parental pa-
tient	 tumors,	 including	 drug	 sensitivity.	One	 such	 approach	 is	 our	
recently developed method to efficiently prepare and culture or-
ganoids	from	primary	tissues	of	colorectal	cancers	(CRC):	the	cancer	
tissue-	originated	 spheroid	 (CTOS)	 method.8 The principle behind 
the	CTOS	method	 is	the	maintenance	of	cell-	cell	contact	through-
out the preparation and culture process. This method provides the 
advantage of efficiently, rapidly and simply preparing pure and sta-
ble	cancer	cells	as	clusters.	Some	CTOS	can	form	xenograft	tumors	
in immuno- deficient mice, with morphology resembling that of the 
originated patient tumor.8	Importantly,	CTOS	are	simple	to	prepare,	
especially from xenograft tumors, enabling their reproducible ap-
plication in multiple experiments.9-12	We	previously	demonstrated	
that	CTOS	exhibit	heterogeneous	responses	to	the	tested	drugs,9,12 
which is critical in models for developing therapeutics and person-
alized medicine.
We	have	used	the	CTOS	method	to	perform	several	small-	scale	
drug	 screening	 trials,	 testing	 approximately	 100	drugs	with	CTOS	
from CRC and endometrial cancer.12-14	However,	with	manual	exper-
iments,	it	is	practically	impossible	to	perform	high-	throughput	(HT)	
screening to test thousands of drugs. Because cell- cell contact is 
retained	throughout	the	procedure	in	the	CTOS	method,	the	well-	




changes in morphological and genomic status, and that xenograft 
tumor	 generation	 efficiently	 expanded	 the	 number	 of	 CTOS,	 en-
abling	high	throughput	screening.	Our	panel	of	30	CRC	CTOS	lines	
exhibited diverse sensitivities to the hit compounds, demonstrating 
the usefulness of this system for investigating highly heterogeneous 
cancers.
2  | MATERIAL S AND METHODS
2.1 | Generation of cancer- tissue originated 
spheroid lines and patient- derived xenograft lines
Surgical specimens, endoscopic biopsy and pleural effusion samples from 
CRC	and	lung	cancer	patients	were	obtained	from	the	Osaka	International	















to generate another passage of xenograft tumors and to reproduce 
the experiments. Tables S1, S2 and S3 present details regarding the 
32	CTOS	 lines	 in	 the	CRC	panel.	The	PDX	 lines	were	established	as	
previously described.15 Table S3 presents details regarding the original 
tumors for the 3 PDX lines. Formalin- fixed paraffin- embedded tissues 
were	used	for	morphological	analysis	of	original	CTOS-	derived	xeno-
graft and patient- derived xenograft tumors.
2.2 | Cancer tissue- originated spheroid preparation
For	both	surgical	 specimens	and	xenografts,	CTOS	were	prepared	
as previously described with slight modifications.8 Briefly, tumors 
were mechanically minced and incubated for 90 minutes at 37°C 
with	 continuous	 stirring,	 in	 DMEM/Ham’s	 F12	 medium	 (Wako	
Pure	 Chemical	 Industries,	 Osaka,	 Japan)	 containing	 Liberase	 DH	
(Roche,	 Basel,	 Switzerland)	 at	 a	 final	 concentration	 of	 .28	units/
mL.	DNase	I	 (Roche)	was	added	at	10	μg/mL, followed by an addi-
tional 15 minutes of incubation. The digestion solution was serially 





Fr.100- 250 samples were mechanically disrupted by raising and low-
ering the plunger several times using a 27- gauge needle, and then 
cultured as described for Fr.40- 100. To generate xenograft tumors 
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2.3 | Library preparation and sequencing for 
exome analysis
In	preparation	for	exome	sequencing	analyses,	extracted	DNA	samples	
from original tumors, normal peripheral blood cells, xenografts and 2D 





with a median coverage of 245- 343 per tumor, 104- 211 per normal.






expressed as px n. Representative 4 lines of colorectal cancer are shown. Scale bar, 100 μm.	B,	Incidence	of	various	genome	alternations	
in	CTOS	lines	of	colorectal	cancer	at	different	passage	numbers.	INDEL,	insertion	or	deletion;	non-	SYN,	non-	synonymous;	SNV,	single-	
nucleotide	variation;	SYN,	synonymous
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(mm9).16 The reads were excluded if they appeared to be derived from 
mouse cells based on the following criteria: reads were properly paired 
when aligned to the mouse genome but not when aligned to the 
human genome, or reads were more similar to the mouse genome than 
the	human	genome	 in	 the	match	 length.	GenomeAnalysisTK	 (GATK)	
ver. 3.4- 46 was used to recalibrate the variant quality score and to 
perform local realignment.17	Somatic	SNV	were	called	using	VarScan	
ver.2.3.7,18 MuTect ver. 1.1.519	 and	 Karkinos	 ver.	 3.0.22	 (H.	 Ueda,	
unpublished).	Somatic	indels	were	detected	using	VarScan	ver.	2.3.7,	
SomaticIndelDetector	 ver.2.3-	9,17	 and	 Karkinos	 ver.	 2.0.1.	 Somatic	
SNV	and	 indels	were	 considered	 genuine	mutations	when	detected	
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2.5 | Assay plate preparation
Cancer tissue- originated spheroids were prepared as described 
above.	After	culturing	for	24	hours,	the	CTOS	were	separated	into	2	
fractions by serially passing through 100- μm and 70- μm cell strainers 
(Corning):	70-	100	μm	(Fr.70-	100)	and	>100	μm	(Fr.	>	100).	Fr.70-	100	
was	 directly	 selected	 and	 plated.	 Fr.	>	100	μm was mechanically 
disrupted,	cultured	for	1	day,	and	then	selected	and	plated.	An	au-
tomated	pipetting	system	(P5073;	Eppendorf,	Hamburg,	Germany)	
was used to dispense 36 μL	of	STEMPRO	hESC	SFM	into	384-	well	
plates	 (PrimeSurface,	Sumitomo	Bakelite,	Tokyo,	 Japan).	Then,	 the	
384-	well	plate	was	seeded	with	1	CTOS	per	well	using	an	automatic	
spheroid	 handler	 (CELL	 HANDLER	 https://global.yamaha-motor.





2.6 | Drug panel for high- throughput screening
The	library	included	2427	drugs	(Table	S4),	including	FDA-	approved	
drugs	 and	 small	 molecules	 with	 known	 targets,	 which	 were	 pro-





1 Bortezomib 10 0.78 1.42 Yes
100 0.02 0.13
2 Gemcitabine 10 0.70 0.28 Yes
100 0.29 0.12
3 Camptothecin 10 0.38 0.62 No
100 0.28 0.13
4 Cabazitaxel 10 0.84 0.75 Yes
100 0.18 0.18
5 Brefeldin	A 10 1.55 1.22 No
100 0.06 0.07




10 0.24 0.79 No
100 0.13 0.29
8 Ouabain 10 0.87 0.67 No
100 0.05 0.06
C45 alone
9 Cladribine 10 1.29 1.39 Yes
100 0.36 0.68
10 Carfilzomib 10 0.93 1.13 Yes
100 0.22 0.88
C132 alone
11 Docetaxel 10 0.88 0.34 Yes
100 0.80 0.32
12 Valproate 10 1.03 0.81 Yes
100 1.31 0.38
13 Clofarabine 10 1.48 1.51 Yes
100 0.48 0.31
14 PD- 180970 10 1.13 0.47 No
100 0.82 0.20
15 CGS- 15943 10 1.52 0.94 No
100 1.48 0.36
TABLE  1 List of hit compounds from 
the screening
Inhibition	ratios	(see	material	and	method)	of	<0.4	are	indicated	in	red	letters.
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Science	Research	(Basis	for	Supporting	Innovative	Drug	Discovery	
and	 Life	 Science	 Research	 [BINDS]).	 Each	 drug	 was	 diluted	 with	
DMSO	and	dispensed	into	384-	well	plates	at	a	final	concentration	
of 10 or 100 nmol/L. Six wells were used for each concentration of 
each	drug.	Control	wells	(DMSO-	treated	and	CTOS-	free	wells)	were	
placed in every plate, with at least 6 wells for each control.
2.7 | Cancer tissue- originated spheroid 
viability assay
After	addition	of	the	drugs,	CTOS	were	cultured	in	5%	CO2 at 37°C 
for	7	days.	Intracellular	ATP	was	measured	using	the	ATPlite	1step	
kit	 (PerkinElmer,	Waltham,	MA,	USA).	Chemiluminescence	was	de-
tected	 by	 Alpha	 Plate	 (PerkinElmer),	 and	 the	 value	 was	 adjusted	
by	CTOS	area	before	drug	addition	at	0,	1,	3,	10,	30,	100,	300	and	
1000	nmol/L.	 Alternatively,	 for	 the	 assay	 on	 PDX-	 derived	 CTOS	
(KC478,	 KC4876	 and	 KC526),	 drugs	 were	 added	 at	 0,	 1,	 10,	 100	




dal dose- response function.
2.8 | Determination of drug efficacy against 
monolayer cell lines
The drug efficacy against established cell lines in monolayer culture 
was assessed based on total cellular protein changes after 48 hours 
of drug treatment in five 10- fold serial dilutions (10−4, 10−5, 10−6, 
10−7 and 10−8	mol/L,	unless	otherwise	specified),	measured	by	sul-
forhodamine	B	assay.	Assays	were	performed	in	duplicate,	and	the	
half-	maximal	 (50%)	 growth	 inhibitory	 concentration	 value	 (GI50)	







the left graph, and the remaining 26 lines are shown on the right
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log-	transformed	 values.	 These	 values	 represent	 the	 drug’s	 efficacy	
profile.	Next,	the	drugs	were	clustered	by	efficacy	profiles,	based	on	
correlation	 coefficients	 with	 other	 drugs	 (average-	linkage	 clustered	
with	Pearson’s	 correlation	metric).	Similarly,	 cells	were	clustered	ac-
cording to their sensitivity profiles across the examined drugs, based 
on correlation coefficients with other cells. Cluster and Treeview soft-
ware	(Eisen	Laboratory,	Stanford	University,	CA,	USA)	were	used	for	
cluster analyses, visualization of clustering results by tree structure, 






3.1 | Generating cancer tissue- originated spheroid- 
derived xenografts without remarkable alteration of 





fully generated xenograft tumors in over 2 passages, and left sufficient 
freeze	stocks,	it	was	deemed	a	successfully	established	CTOS	line.
We	next	evaluated	how	well	CRC	CTOS	retained	characteristics	of	
their originated patient tumors after in vivo passages. Established cell 
lines reportedly lose characteristics of the original tumors,5 accumu-
lating mutations and losing morphological features even in xenograft 
tumors.8	We	compared	histology	between	xenograft	tumors	at	differ-
ent	passages	and	 the	original	patient	 tumors	 (Figure	1A),	and	 found	
good retention of morphological characteristics of the original tumors, 








and evaluation of diversity.
3.2 | High- throughput screening of 2427 drugs on 2 




a specific range of size and quality into each well to test thousands of 
drugs.	Thus,	we	used	 an	 automatic	 system	 to	 select	CTOS	meeting	
morphological	criteria,	and	to	dispense	them	individually.	CTOS	were	
selected based on size (70- 100 μm)	 to	 minimize	 the	 effect	 of	 hy-
poxia	after	growth	and	on	appearance	(transparency)	to	exclude	the	
clusters	of	dead	cells	(Figure	2A).	Two	CRC	lines	were	used	for	high-	
throughput screening: the fast- growing C45 line and the slow- growing 
C132	line.	Figures	2B,C	show	the	variations	of	CTOS	size	and	growth.	
We	screened	a	total	of	2427	drugs	(Table	S4)	at	relatively	low	doses	
(10	and	100	nmol/L)	 for	 their	 ability	 to	 suppress	cancer	cell	 growth	
(Figure	2D).	Of	these	2427	drugs,	we	identified	15	(.6%)	hit	drugs	that	
inhibited	CTOS	viability	down	to	40%	of	control	(Table	1),	of	which	8	
drugs were effective against both lines, 2 drugs against C45 alone, and 
5 drugs against C132 alone; 10 drugs were anti- cancer reagents and 7 
were	FDA-	approved.
3.3 | Hit drug evaluation using a panel of 30 
colorectal cancer tissue-originated spheroid
To evaluate the diversity of sensitivity among the 15 hit drugs in vari-
ous	CTOS	lines,	we	used	a	CRC	CTOS	panel	comprising	30	lines	(Tables	








tested	 in	 30	 CTOS	 lines,	 and	 observed	 substantial	 variation	 in	 the	
sensitivity to each compound, which differed among the compounds 
(Figures	4A,	S2).	The	drugs	valproate	and	PD-	180970	were	 ineffec-












There	 are	 drugs	 that	worked	better	 in	CTOS	on	 the	 right	 side,	 and	
less	efficiently	 in	CTOS	on	the	 left,	 indicating	the	complexed	nature	
of	drug	sensitivity.	In	addition,	these	2	groups	of	different	drug	sen-
sitivity are not a mere reflection of the difference in the basal growth 
of	each	CTOS	lines	(Figure	4C,	bottom).	Based	on	the	clustering	anal-




mode of action exhibited significant correlation (Figure 4D left and 
middle	panels),	while	drugs	with	different	mode	of	action	showed	no	
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F IGURE  4 Diversity	 of	 sensitivities	 for	 the	 hit	 drugs	 among	 colorectal	 cancer	 (CRC)	 cancer	 tissue-	originated	 spheroid	 (CTOS)	
lines.	A,	Dose-	response	 curves	 of	 15	drugs	 in	 the	panel	 of	CRC	CTOS	 lines.	B,	Morphological	 changes	 after	 treatment	with	100	nmol/L	
of	carfilzomib.	C,	Heat	map	and	clustering	analysis	of	 the	average	 IC50	of	15	drugs	 in	 the	CTOS	panel.	The	heat	map	 is	 shown	as	 the	−
log	of	 IC50	subtracted	from	the	average	for	each	drug.	Bar	graph	shows	the	mean	growth	of	each	CTOS	 line	at	basal	condition,	which	 is	
extracted	 from	Figure	3C.	D,	 Ranks	 of	 the	 sensitivity	 of	 CTOS	 lines	 toward	 bortezomib	 and	 carfilzomib	 (left),	 docetaxel	 and	 cabazitaxel	
(middle),	and	docetaxel	and	bortezomib	(right)	are	presented	in	diagrams.	R- value and P-	value	were	analyzed	by	Spearman’s	rank	correlation
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correlation	(Figure	4D,	right	panel).	These	data	indicate	that	the	assay	
correctly reflected the mode of action.
3.4 | Diversity of sensitivity among cancer tissue- 
originated spheroids from the colorectal cancer panel
We	next	 compared	 our	 results	 in	CRC	CTOS	with	 the	 findings	 of	
JFCR39, which is a panel of 39 human cancer cell lines coupled 





parameters were used, these average values showed a good cor-
relation (r2	=	.4076).	Five	drugs	 (diphenyleneiodonium,	clofarabine,	













ing the extent of response heterogeneity, although the reason of the 







spheroids have been generated as the aggregates of established 
cell lines.4	Organoid	methods	have	previously	been	used	for	smaller	
scale screenings of 16- 160 drugs.24-26	To	our	knowledge,	this	is	the	
first report to describe high- throughput screening of over 2000 
compounds	 in	 a	 3D	 culture.	 The	 present	 CTOS	 method	 enabled	
the	preparation	of	a	large	number	of	CTOS	from	xenograft	tumors	
(Figure	3A),	requiring	only	several	hours	for	the	preparation	of	can-
cer	 cells	 from	 tumor	 tissue,	 and	 enabling	 overnight	 CTOS	 forma-
tion.	Moreover,	the	cells	comprising	the	CTOS	showed	high	viability	
and stability compared to the primary cells dissociated into single 
cells.8,27	 These	 advantages	 of	 CTOS	 enabled	 the	 high	 throughput	
screening using 3D and ex vivo culture.
The	CTOS	method	supports	ex	vivo	applications	of	mouse	xe-
nografts, including high- throughput screening, as in our present 
study, genetic manipulation of cancer cells,10,11 and detailed analysis 
of intracellular signaling in response to various stimuli.9,12	Notably,	
CTOS	can	be	freeze-	stocked	with	an	excellent	recovery	rate,	help-




tumor	within	 approximately	 1	month	 (Figure	3A).	 Thus,	 the	 CTOS	
method	complements	mouse	xenograft	methods.	We	demonstrated	
that	 some	 genomic	 changes	 occurred	 in	 CTOS	 throughout	 5	 pas-
sages	via	mouse	xenografts	(Figures	1B,	S1B),	such	as	passaged	tu-
mors of PDX.28	One	should	keep	in	mind	this	slight	genomic	changes	
might affect the results of sensitivity assay and can be the cause 
for	a	discrepant	result	with	patient’s	clinical	response,	when	clinical	
application is the subject of a study.
Our	present	results	showed	that	drug	sensitivity	substantially	
varied	among	the	CTOS	 lines.	This	variation	of	sensitivity	 is	 rele-
vant to 2 different aspects of application. First, as shown in this 
study,	 sensitivity	 ranking	 enables	 assessment	 of	 the	 sensitivity	
of	an	individual	CTOS	relative	to	a	reference	panel	of	CTOS	lines	
(Figure	5C).	Using	more	lines	as	the	reference	would	 increase	the	
accuracy of the prediction. This method might be useful in the se-
lection of drugs for individual patients in future, especially when 
the drugs are tested in clinical trials that indicate the variable sensi-
tivity among patients. For this application, technical improvements 
in	the	preparation	of	CTOS	from	patient	tumor	biopsy	samples	 is	
critical	to	test	multiple	drugs	for	each	patient.	Although	CTOS	lines	
did not change significantly over several passages in terms of histol-
ogy	and	mutations,	the	quality	of	CTOS	for	the	purpose	of	person-
alized drug selection should be carefully considered: for example, 
a possible single mutation over ex vivo passage could change the 
drug	sensitivity.	Second,	classifying	CTOS	lines	 into	sensitive	and	
resistant groups with large collections of PDX and organoids might 
help	in	biomarker	identification.
Because	a	CTOS	comprises	pure	cancer	cells,8	 the	CTOS	sensi-
tivity assay in our study would not fully reflect the complex tumor 
microenvironment.	Non-	physiological	oxygen	concentration	may	be	
another	 issue.	 Nonetheless,	 it	 provides	 important	 information	 be-
cause cancer cell sensitivity per se is one of the critical factors in a 
patient’s	drug	sensitivity.	For	some	of	the	drugs	used	in	clinic,	CTOS	
sensitivity assay results were consistent with the reported results of 
clinical	trials	specifically	in	the	cases	of	an	EGFR	tyrosine	kinase	inhib-
itor in lung cancer9 and an anti- EGFR antibody in colorectal cancer.12 
However,	the	clinical	relevance	of	the	CTOS	sensitivity	assay	should	
be further assessed in prospective clinical trials, such as a recent study 
that compared the drug responses of patient- derived gastrointestinal 
organoids with the responses of the patients in the clinic.29	 It	may	
be necessary to optimize the culture conditions for each drug9,12 to 
better reflect the clinical responses of individual patients to the drug.
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